The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- Jill Hallin1
- Lars D. Engstrom1
- Lauren Hargis1
- Andrew Calinisan1
- Ruth Aranda1
- David M. Briere1
- Niranjan Sudhakar1
- Vickie Bowcut1
- Brian R. Baer2
- Josh Ballard2
- Michael R. Burkard2
- Jay B. Fell2
- John P. Fischer2
- Guy P. Vigers2
- Yaohua Xue3
- Sole Gatto4
- Julio Fernandez-Banet4
- Adam Pavlicek4
- Karen Velastagui1
- Richard C. Chao1
- Jeremy Barton1
- Mariaelena Pierobon5
- Elisa Baldelli5
- Emanuel F. Petricoin5
- Joseph Jacobson6
- Matthew A. Marx1
- Igor I. Rybkin7
- Melissa L. Johnson8
- Sai-Hong Ignatius Ou9
- Piro Lito3
- Kyriakos P. Papadopoulos10
- Pasi A. Jänne6
- Peter Olson1
- James G. Christensen1
- 1. Mirati Therapeutics, Inc., San Diego, CA, 92121, USA
- 2. Array BioPharma Inc., Boulder, CO, 80301, USA
- 3. Memorial Sloan Kettering Cancer Center, New York City, NY, 10065, USA
- 4. Monoceros Biosystems LLC, San Diego, CA, 92130, USA
- 5. George Mason University, Manassas, VA, 22030, USA
- 6. Dana Farber Cancer Institute, Boston, MA, 02215, USA
- 7. Henry Ford Medical Center, Detroit, MI, 48202, USA
- 8. Sarah Cannon Research Institute Tennessee Oncology, Nashville, TN, 37203, USA
- 9. University of California, Irvine, Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USA
- 10. START Center for Cancer Care, San Antonio, TX, 78229, USA
Description
We directly interrogated the role of selected genes in mediating therapeutic response to MRTX849 utilizing a focused CRISPR/Cas9 knockout screen targeting approximately 400 genes including many genes involved in KRAS signaling. This was conducted in H358 and H2122 cells in vitro and in H2122 xenografts in vivo in presence and absence of MRTX849 treatment.
Three independent drug anchored CRISPR studies were performed and two data files have been provided for each study. The .csv metadata files contain sample IDs, replicate number, sample descriptions and various experimental conditions. The .xlsx data files contain guide labels, guide sequences and NGS guide counts.Three independent drug anchored CRISPR studies were performed and two data files have been provided for each study. The .csv metadata files contain sample IDs, replicate number, sample descriptions and various experimental conditions. The .xlsx data files contain guide labels, guide sequences and NGS guide counts.
Files
S4570_H358_invitro_CRISPR_Screen_meta.csv
Files
(1.1 MB)
| Name | Size | |
|---|---|---|
|
md5:ee3d2b295c55510cbf068e8eb3bb5f27
|
23.1 kB | Download |
|
md5:f8d7496029aef4340ab4438e2c5e65af
|
260.2 kB | Download |
|
md5:3cd75fcbddf294d2a4e26d91779b441d
|
292 Bytes | Preview Download |
|
md5:acdc16cc25e6fe722af1f9c8d14092c6
|
287.1 kB | Download |
|
md5:eadff6665b5fb131c656b356acbe020a
|
348 Bytes | Preview Download |
|
md5:20e5d2eeae3f3b57451444d40ce44e19
|
572.7 kB | Download |
|
md5:54ffe77fb109963b2aabc7ccd203f412
|
1.3 kB | Preview Download |
Additional details
References
- Hallin, Jill et al., Cancer Discov. 2020. CRISPR dataset associated to: doi: 10.1158/2159-8290.CD-19-1167